Head-to-head · Cost-Efficiency Index
Boston Medical Group vs Layla
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Boston Medical Group
Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate.
Visit Boston Medical GroupLayla
Cost-first shoppers who want brand-name GLP-1 access from shoppers who don't need a compounded/lower-cost option.
Visit LaylaThe verdict
Boston Medical Group and Layla tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with Boston Medical Group (ranked #269, a hair above #274) — Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate. But Layla is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Boston Medical Group.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Boston Medical Group | Layla |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $199/mo (starting strength, rising with dose, compounded) | $1,399/mo (brand Ozempic, promotional rate) |
| Tirzepatide / mo | Not disclosed | $1,399/mo (brand Mounjaro, promotional rate) |
| Semaglutide / yr (modeled) | $2,388 | $16,788 |
| Tirzepatide / yr (modeled) | — | $16,788 |
| Coverage | 7 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #269 | #274 |
Boston Medical Group
59/100Where the value is
- An established medical group with a defined 12-week program rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
The tradeoffs
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week program totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
Layla
59/100Where the value is
- All-inclusive pricing bundles health check-ins, telehealth visits, prescription and unlimited doctor messaging into one price
- Named Medical Director (Dr. Ruth Cohen) disclosed on-site
- LegitScript-certified badge displayed; fast 2-3 day shipping claimed
The tradeoffs
- Brand-only and expensive: the real floor is $1,399/mo (Ozempic/Mounjaro), not the $1,299 the homepage FAQ separately claims — the two figures don't reconcile
- The lowest Zepbound figure shown ($1,599) is a one-time new-customer discount off a $1,699 standing price, not an ongoing rate
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.